Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Mebufotenin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 0.76 |
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 4/20 | 0.76 |
| ▸ | HTR6 | P50406 | 3/20 | 0.76 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.76 |
| ▸ | HTR3B | O95264 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | HTR1E | P28566 | 1/20 | 0.76 |
| ▸ | HTR1F | P30939 | 1/20 | 0.76 |
| ▸ | HTR7 | P34969 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | HTR3A | P46098 | 1/20 | 0.76 |
| ▸ | HTR5A | P47898 | 1/20 | 0.76 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.76 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebufotenin SCHEMBL7205139 | 0.90 | KMT2A (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL31098269 | 0.87 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL132733 | 0.87 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL29351950 | 0.87 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL27221706 | 0.87 | HTR1D (1.00) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL30199593 | 0.86 | KMT2A (0.84) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL23927938 | 0.86 | KMT2A (0.84) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL25330504 | 0.86 | HTR1D (0.97) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Mebufotenin SCHEMBL26111484 | 0.86 | HTR1D (0.97) | KMT2AHTR1DHTR1BHTR1AHTR6 | |
| Oxalic Acid SCHEMBL8869617 | 0.83 | KMT2A (0.87) | KMT2AHTR1DHTR1BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | BECKLEY PSYTECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260035334-A1 | METHOD OF SYNTHESIS | BECKLEY PSYTECH LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| WO-2025068714-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) | Beckley Psytech Limited (GB) | 2025-04-03 | — | — | WO | disclosed |
| EP-4279070-B1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | BECKLEY PSYTECH LTD (GB) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448488-A2 | BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111544-A2 | BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035334-A1 | METHOD OF SYNTHESIS | HTR5A, HTR1A, HTR2C | HTR1D 19/4885HTR1B 16/4885KMT2A 104/4885 |
| US-20260041667-A1 | PRESCRIPTION DIGITAL THERAPEUTICS | HTR5A, PNMT, NPY5R | HTR1D 359/4885HTR1B 226/4885KMT2A 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.